Regulatory Insights from EMA CHMP Meeting Highlights
The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal gel for Parkinson’s motor fluctuations, a once-weekly insulin for type 2 diabetes, and two biosimilars for cancer-related skeletal complications and chemotherapy-induced neutropenia.
Full CHMP recommendations also included a re-examination success for a Rett syndrome neurobehavioural treatment, later restricted to patients five years and older.
Re-Examination Flips Initial Refusal
A formal re-examination procedure reversed an earlier negative opinion for the Rett syndrome medicine after deeper review of its impact on repetitive movements, anxiety, and communication deficits. This outcome demonstrates how structured appeal pathways can refine indications when additional evidence is compelling.
Advanced Therapies Fall Short
Three applications received negative opinions, including an autologous TIL therapy for advanced melanoma, a treatment for transplant-associated thrombotic microangiopathy, and an allogeneic faecal microbiota product for acute graft-versus-host disease. The decisions reinforce the committee’s insistence that clinical benefit must clearly outweigh risk in high-stakes settings.
Extensions Broaden Patient Reach
Eleven existing medicines gained expanded indications, most notably lowering the minimum age for a modified vaccinia Ankara vaccine from 12 to 2 years for smallpox, mpox, and vaccinia protection. The committee also incorporated cardiovascular outcomes data for a tirzepatide product into its labelling despite declining a formal expanded claim.
Data Integrity Triggers Revocation
Safety and quality referrals under Article 31 led to the revocation of a medicine for severe granulomatosis with polyangiitis and microscopic polyangiitis after unresolved concerns about pivotal trial integrity. Similar scrutiny continues for a rifampicin oral suspension regarding potential excipient carcinogenicity observed in animal studies.
EMA CHMP Meeting Highlights Shape Future Access
These EMA CHMP Meeting Highlights send clear signals to developers about the level of evidence required for oncology, immunology, and rare-disease programmes in Europe. By approving select innovations, narrowing labels, and revoking approvals where standards slipped, the committee directly influences which therapies reach clinicians and patients across the EU.
Summary of Key CHMP Decisions (22-25 June 2026)
| Category | Product Name | Active Substance / Type | Key Indication / Change | Notes / Applicant |
|---|---|---|---|---|
| New Medicine | Aujemflu | Inactivated influenza vaccine | Prophylaxis of influenza in adults ≥50 years | Seqirus Netherlands BV |
| New Medicine | Hopledo | Levodopa / carbidopa | Parkinson’s disease with motor fluctuations in adults | Zambon S.p.A. |
| New Medicine | Onswik | Insulin efsitora alfa | Treatment of type 2 diabetes mellitus in adults | Eli Lilly Nederland B.V. |
| Biosimilar | Denosumab Ascend | Denosumab (biosimilar) | Prevention of skeletal-related events in advanced cancer; giant cell tumour of bone | Ascend GmbH |
| Biosimilar | Nylaspeg | Pegfilgrastim (biosimilar) | Reduction of neutropenia and febrile neutropenia due to chemotherapy | Qilu Pharma Spain S.L. |
| Re-examination | Daybu | Trofinetide | Neurobehavioural symptoms of Rett syndrome (adults & paediatrics ≥5 years) | Acadia Pharmaceuticals (Netherlands) B.V. (Orphan) |
| Negative Opinion | Tacquell | Autologous TIL therapy | Advanced melanoma | Netherlands Cancer Institute |
| Negative Opinion | Yartemlea | Narsoplimab | HSCT-associated thrombotic microangiopathy | Omeros Ireland Limited (Orphan) |
| Negative Opinion | Xervyteg | Allogeneic faecal microbiota | Acute graft-versus-host disease (aGvHD) | MaaT PHARMA |
| Extension | Imvanex | Modified vaccinia Ankara vaccine | Lowered minimum age to ≥2 years (smallpox, mpox, vaccinia) | Bavarian Nordic A/S |
| Extension (other) | Datroway, Jaypirca, Leqvio, Menquadfi, Opzelura, Rezolsta, Rinvoq, Stelara, Symtuza, Tecvayli | Various | Various expanded indications | Multiple holders |
| Referral – Revocation | Tavneos | Avacopan | Granulomatosis with polyangiitis (GPA) / microscopic polyangiitis (MPA) | Revoked due to data integrity concerns |
| Referral – Review | Rifadin | Rifampicin oral suspension | Review due to excipient (DEA) carcinogenicity concerns | Ongoing |
| Other Update | Mounjaro | Tirzepatide | CV outcomes data added to labelling (no formal new indication) | Eli Lilly |
Source: Official EMA CHMP Meeting Highlights (22-25 June 2026). This HTML version includes a structured summary table for quick reference.
Recent Posts
KEYTRUDA Combination Therapy Gains FDA Approval for Advanced Triple-Negative Breast Cancer
Innovations in Calcified Carotid Lesion Preparation for Enhanced Stroke Management
